SRP3132

Osteoprotegerin (OPG) human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

• Synonym(e): OCIF (osteoclastogenesis inhibitory factor), OPG, TNFRSF11B, TR1
• UNSPSC-Code: 12352202
• NACRES: NA.32

Eigenschaften

• Biologische Quelle: human
• Rekombinant: expressed in E. coli
• Assay: ≥98% (HPLC); ≥98% (SDS-PAGE)
• Form: lyophilized
• Mol-Gew.: 20.0 kDa
• Verpackung: pkg of 50 μg
• Methode(n): cell culture | mammalian: suitable
• Verunreinigungen: <0.1 EU/μg endotoxin, tested
• Farbe: white to off-white
• UniProt-Hinterlegungsnummer: O00300
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• Angaben zum Gen: human ... TNFRSF11B(4982)

Beschreibung

Allgemeine Beschreibung

Osteoprotegerin (OPG) is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor κ-B ligand).[1][2] The gene is mapped to human chromosome 8q24.[1] The primary structure of OPG protein consists of seven distinct domains, four of which corresponds to the extracellular cysteine-rich domains of TNFR proteins and constitutes the soluble OPG.[3] OPG is expressed in a wide variety of tissues including adult heart, lung, kidney, liver, spleen, prostate, lymph node and bone marrow. It is secreted both as a monomeric and a dimeric protein.[2][3] Recombinant human OPG is a soluble 20kDa protein containing 174 amino acid residues.

Anwendung

Osteoprotegerin (OPG) human has been used as a supplement in human cell culture during cytokine production.[4]

Biochem./physiol. Wirkung

Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, thereby leading to excess accumulation of bone and cartilage.[2] Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders.[5] It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma.[6]

Sequenz

METFPPKYLH YDEETSHQLL CDKCPPGTYL KQHCTAKWKT VCAPCPDHYY TDSWHTSDEC LYCSPVCKEL QYVKQECNRT HNRVCECKEG RYLEIEFCLK HRSCPPGFGV VQAGTPERNT VCKRCPDGFF SNETSSKAPC RKHTNCSVFG LLLTQKGNAT HDNICSGNSE STQK

Physikalische Form

Lyophilized from 10 mM Tris pH, 7.5 + 75 mM NaCl.

Rekonstituierung

Centrifuge the vial prior to opening. Reconstitute in 5 mM Tris, pH 7.5 to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable